SFS
ARKG icon

Summit Financial Strategies’s ARK Genomic Revolution ETF ARKG Stock Holding History

Summit Financial Strategies’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,112
Closed -$235K – 120
2022
Q1 		$235K Hold
5,112
– – 0.05% 102
2021
Q4 		$313K Buy
5,112
+260
+5% +$18K 0.06% 90
2021
Q3 		$363K Hold
4,852
– – 0.07% 77
2021
Q2 		$449K Buy
4,852
+1,998
+70% +$170K 0.09% 70
2021
Q1 		$253K Buy
+2,854
New +$283K 0.09% 58

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Summit Financial Strategies's ARKG Position: Q2 2022 in Review

Summit Financial Strategies sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 5,112 shares — an estimated $235K sold.

Summit Financial Strategies first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $449K in Q2 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Summit Financial Strategies reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Summit Financial Strategies sold 5,112 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $235K.
  • Summit Financial Strategies first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
  • Summit Financial Strategies's ARK Genomic Revolution ETF position peaked at $449K in Q2 2021.
  • 333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Summit Financial Strategies's 13F filing for Q2 2022, filed 25 Jul 2022.